K-Ras inhibitors (Dana-Farber Cancer Institute/Astellas)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameK-Ras inhibitors (Dana-Farber Cancer Institute/Astellas)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A